4-HETEROARYL-3-HETEROARYLIDENYL-2-INDOLINONES AND THEIR USE AS PROTEIN KINASE INHIBITORS
申请人:Sugen, Inc.
公开号:EP1296975A1
公开(公告)日:2003-04-02
US6635640B2
申请人:——
公开号:US6635640B2
公开(公告)日:2003-10-21
US7053086B2
申请人:——
公开号:US7053086B2
公开(公告)日:2006-05-30
[EN] 4-HETEROARYL-3-HETEROARYLIDENYL-2-INDOLINONES AND THEIR USE AS PROTEIN KINASE INHIBITORS<br/>[FR] 4-HETEROARYL-3-HETEROARYLIDENYL-2-INDOLINONES ET LEUR UTILISATION COMME INHIBITEURS DES PROTEINE KINASES
申请人:SUGEN INC
公开号:WO2002002551A1
公开(公告)日:2002-01-10
The present invention relates to certain 4-heteroaryl-3-heteroarylidenyl-2-idolinones compounds and their physiologically acceptable salts which modulate the activity of protein kinases ('PKs'), in particular CDK2. The compounds of the present invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical composition containing these compounds and methods of preparing these compounds are also described.
4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
申请人:——
公开号:US20020187978A1
公开(公告)日:2002-12-12
The present invention relates to certain 4-heteroaryl-3-heteroarylidenyl-2-indolinones compounds and their physiologically acceptable salts which modulate the activity of protein kinases (“PKs”), in particular CDK2. The compounds of the present invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical composition containing these compounds and methods of preparing these compounds are also described.